GC Pharm acquires approval of ‘Glargia’ referencing insulin glargine

GC Pharm(CEO Eun-Cheol Huh) announced on the 9^th that the company acquired approval of ‘Glargia(insulin glargine),’ an antidiabetic biosimilar(bioequivalently tested) from the Ministry of Food and Drug Safety.

The original product of ‘Glargia’ is ‘Lantus’ developed by Sanofi, a multinational pharmaceutical company, which is a medicinal drug which made over 4.6 billion euros last year in the wo...